Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q14344
UPID:
GNA13_HUMAN
Alternative names:
-
Alternative UPACC:
Q14344; B2R977; B7Z7R0; F5H1G8; Q8TD70
Background:
Guanine nucleotide-binding protein subunit alpha-13 (GNA13) plays a pivotal role in cellular signaling by acting as a modulator in transmembrane signaling systems. It activates the effector molecule RhoA through interaction with RhoGEFs, influencing various cellular processes including transcription factor AP-1 regulation. GNA13's involvement extends to promoting tumor cell invasion and metastasis via the RhoA/ROCK signaling pathway and modulating cell adhesion independently of Rho activation.
Therapeutic significance:
Understanding the role of Guanine nucleotide-binding protein subunit alpha-13 could open doors to potential therapeutic strategies, particularly in targeting mechanisms of tumor progression and metastasis.